Celularity Inc

CELUNASDAQ · USD
0.46USD0.00 (-1.05%)
232

Celularity Inc (CELU) Unusual Options Activity Today

Read more

Checking CELU unusual options activity helps you spot when traders are making outsized bets on Celularity Inc before the broader market catches on. Unusual activity flags contracts trading at multiples of their average daily volume, often signaling informed money positioning ahead of a catalyst. Use our scanner to monitor CELU unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically means volume vastly exceeds open interest at a given strike, or total contract volume on a name spikes well above its norm. Watching CELU unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CELU unusual options volume across calls and puts helps you separate hedging from genuinely speculative positioning, especially valuable around earnings, product launches, and macro events.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

2026-12-18
Calls
0.50—0.950.951,000%00—
1.00—0.050.05300%01170.00%
1.50—1.001.001,000%00—
2.00—1.001.001,000%00—
2.50—0.750.751,000%00—
Puts
0.50—0.750.751,000%00—
1.000.450.750.60329%10—
1.500.651.651.15513%00—
2.001.252.251.75769%00—
2.501.752.752.25809%00—

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →